LifeSci Capital initiated coverage of Candel Therapeutics (CADL) with an Outperform rating and $16 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Pulendran to Candel’s RAB
- Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
- Candel Therapeutics Secures $130M Loan for Trials
- Candel Therapeutics enters into $130M term loan facility
- Candel Therapeutics announces interim data from phase 1b CAN-3110 trial